Artivion, Inc. AORT

AORT Company Overview

Artivion, Inc. is a U.S.-based medical device and biotechnology company focused on products used in cardiac and vascular surgery. The company develops, manufactures, and markets implantable biological, mechanical, and synthetic devices used primarily in the treatment of aortic disease, cardiac valve disorders, and complex vascular conditions. Artivion operates within the broader cardiovascular medical technology industry, serving hospitals, cardiac surgeons, vascular surgeons, and specialized surgical centers. Its primary revenue drivers include aortic stent grafts, surgical sealants, mechanical and tissue heart valves, and preserved human cardiac and vascular tissues.

The company traces its origins to CryoLife, Inc., which was founded in 1984 and initially focused on cryopreserved human tissues for cardiac surgery applications. Over time, the business expanded through internal development and acquisitions into medical devices and aortic repair technologies. In 2022, CryoLife officially changed its name to Artivion, Inc. to reflect a broader strategic focus on aortic disease innovation and cardiovascular surgery solutions. The company’s positioning is supported by its combination of biologic tissue expertise, proprietary surgical technologies, and integrated product offerings for complex aortic procedures.